https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Unique approach to continuing medical education in clinical pharmacology across Australia and New Zealand https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37568 Thu 18 Feb 2021 16:08:21 AEDT ]]> Correlates of pain in an in-treatment sample of opioid-dependent people https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17227 Sat 24 Mar 2018 07:59:16 AEDT ]]> Comparing treatment-seeking codeine users and strong opioid users: findings from a novel case series https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23860 Sat 24 Mar 2018 07:12:11 AEDT ]]> Treating codeine dependence with buprenorphine: dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23970 -1 (mean: 564 mg; 95% confidence interval 431-696 mg). Median buprenorphine dose was 12.0 mg (interquartile range 9.5 mg, range 4-32 mg) at day 7 and 16.0 mg (interquartile range 13.5 mg, range 4-32 mg) at day 28. Buprenorphine doses received were markedly higher than estimated codeine doses based on standard dose conversion tables.Discussion and Conclusions: With increasing presentations relating to codeine dependence, these findings provide important guidance to clinicians. Buprenorphine doses were consistently higher than doses estimated based on the dose of codeine consumed, and were comparable with doses used in the treatment of dependence with heroin and more potent prescription opioids.]]> Sat 24 Mar 2018 07:10:05 AEDT ]]>